Sponsors (7)
The bill aims to improve safety, quality, and U.S. access to FDA-regulated products through targeted overseas engagement with Abraham Accords partners and better congressional reporting, while requiring new federal resources and creating potential security, diplomatic, and prioritization trade-offs.
Manufacturers and patients in Abraham Accords countries receive targeted FDA technical assistance to strengthen regulatory oversight and good manufacturing practices, which can improve the safety and quality of FDA-regulated products.
U.S. consumers could gain clearer regulatory pathways and better-aligned standards that facilitate access to safe, effective FDA-regulated products from Abraham Accords countries.
Congress and the public get improved transparency and oversight through a required report with metrics on FDA's foreign engagement (conformance evaluations, counts of interactions, summaries of assistance).
Taxpayers and the federal budget will face increased costs to establish and staff a new overseas FDA office, which could require additional federal spending or divert personnel from domestic priorities.
Federal employees and U.S. interests could face diplomatic or security risks from placing an FDA office abroad, and coordination with security authorities may delay regulatory activities.
State governments and other foreign regulatory partners may be disadvantaged because concentrating FDA engagement on Abraham Accords countries narrows focus and could be perceived as preferential.
Based on analysis of 2 sections of legislative text.
Introduced March 3, 2025 by Diana Harshbarger · Last progress March 3, 2025
Creates a new office inside the Food and Drug Administration to work directly with regulatory authorities and manufacturers in countries party to the Abraham Accords. The office, led by a director and to be located in an Abraham Accords country, will provide technical assistance, promote alignment of regulatory standards (including good manufacturing practices), facilitate interactions between FDA and foreign stakeholders, and report progress to Congress within three years.